YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

Expanded access is no longer available for this treatment.
Sponsor:
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by (Responsible Party):
University of Texas Southwestern Medical Center
ClinicalTrials.gov Identifier:
NCT01427582
First received: August 30, 2011
Last updated: NA
Last verified: August 2011
History: No changes posted

August 30, 2011
August 30, 2011
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access
YONDELIS(Trabectedin) Single Patient Compassionate Use / Expanded Access in Soft Tissue Sarcoma

The YONDELIS (trabectedin) Single Patient Compassionate Use /Expanded Access program provides patients with advanced soft tissue sarcoma, who do not qualify for ongoing clinical trials with YONDELIS (trabectedin), access to this investigational treatment.

The single patient treatment instructions for use are intended for a single patient with advanced soft tissue sarcoma. The patient will be treated with YONDELIS® (trabectedin) i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days, provided that he/she fulfills all eligibility criteria.

The patient may continue to receive therapy until there is evidence of disease progression or unacceptable toxicity. Safety will be evaluated and serious adverse events will be reported. Disease assessments will occur according to institutional practice.

Expanded Access
Not Provided
Not Provided
Soft Tissue Sarcoma
Drug: Trabectedin
Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
Other Name: YONDELIS
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
No longer available
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  1. Signed informed consent.
  2. 18 years-of-age or older.
  3. Unresectable, advanced or metastatic, histologically proven soft tissue sarcoma.
  4. Recovery from toxic effects of prior therapies to NCI CTC Grade 1 or better.
  5. Hematologic variables:

    • Hemoglobin ≥9 g/dL
    • ANC ≥1,500/μL
    • Platelet count ≥100,000/μL
  6. Serum creatinine ≤ upper limit of normal (ULN)
  7. Hepatic function variables:

    • Total bilirubin ≤ ULN
    • Total alkaline phosphatase ≤ ULN, or if > ULN, then alkaline phosphatase liver fraction or 5'-nucleotidase must be ≤ ULN.
    • AST (serum aspartate transaminase [SGOT]) and ALT (serum alanine transaminase [SGPT]) must be ≤ 2.5xULN
    • Albumin ≥2.5 g/dL

Exclusion Criteria:

  1. Pregnant or breast-feeding women, or patients (male or female) not employing adequate contraception. Acceptable means of birth control include IUD, oral contraceptive, subdermal implant, and a condom with a contraceptive sponge or suppository.
  2. Less than 4 weeks from last dose of systemic cytotoxic therapy, radiation therapy, or therapy with any investigational agent
  3. Active viral hepatitis or chronic liver disease
  4. Unstable cardiac condition, including congestive heart failure or angina pectoris, myocardial infarction within 1 year before enrollment, uncontrolled arterial hypertension or arrhythmias
  5. Active infection
Both
18 Years to 90 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01427582
05- EAP- STS
Not Provided
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Principal Investigator: John C. Bagwell, MD University of Texas
University of Texas Southwestern Medical Center
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP